Mechanism

treatment

comparator

All cause death

Bleeding

Cardiovascular death

MACE

Revascularization

Major bleeding

Vascular death

Non fatal stroke

Non fatal MI

ischemic stroke

Non vascular death

stroke (fatal and non fatal)

myocardial infarction (fatal and non fatal)

cardiovascular events

Stent thrombosis (any, end of follow up)

non cardiovascular death

death, MI, unplanned revascularization

ischemic events + bleeding

major bleeding TIMI

TIMI minor bleeding

refractory ischemia

fatal bleeding

Major or minor TIMI bleeding

Urgent target-vessel revascularization

all cause death, MI, stroke

net benefit

stent thrombosis

Elinogrel

acute coronary syndrome, in all type of patients

vs placebo

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
Bleeding	no data
Cardiovascular death	no data
MACE	no data
Revascularization	no data
Major bleeding	1.06 [0.02 54.90]	p=1.00	0	70	1	ERASE-MI,
Major bleeding	1.06 [0.02 54.90]	p=1.00	0	70	1	ERASE-MI,
Vascular death	no data
Non fatal stroke	3.18 [0.12 80.77]	p=1.00	0	70	1	ERASE-MI,
Non fatal MI	1.06 [0.02 54.90]	p=1.00	0	70	1	ERASE-MI,
ischemic stroke	no data
Non vascular death	no data
stroke (fatal and non fatal)	no data
myocardial infarction (fatal and non fatal)	no data
cardiovascular events	no data
Stent thrombosis (any, end of follow up)	no data
non cardiovascular death	no data
death, MI, unplanned revascularization	no data
ischemic events + bleeding	no data
major bleeding TIMI	no data
TIMI minor bleeding	no data
refractory ischemia	no data
fatal bleeding	no data
Major or minor TIMI bleeding	no data
Urgent target-vessel revascularization	no data
all cause death, MI, stroke	no data
net benefit	no data
stent thrombosis	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
ERASE-MI, 2009	elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus	placebo	STEMI patients

Ticagrelor

acute coronary syndrome, in all type of patients

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.79 [0.69 0.90]	p=0.04	0	19285	2	PLATO, DISPERSE-2 (90mg),
Bleeding	1.04 [0.95 1.14]	p=1.00	0	19285	2	PLATO, DISPERSE-2 (90mg),
Cardiovascular death	no data
MACE	no data
Revascularization	no data
Major bleeding	1.02 [0.92 1.14]	p=1.00	0	19285	2	PLATO, DISPERSE-2 (90mg),
Major bleeding	1.02 [0.92 1.14]	p=1.00	0	19285	2	PLATO, DISPERSE-2 (90mg),
Vascular death	0.80 [0.70 0.92]	p=0.04	0	19285	2	PLATO, DISPERSE-2 (90mg),
Non fatal stroke	no data
Non fatal MI	no data
ischemic stroke	1.05 [0.79 1.40]	p=1.00	0	18624	1	PLATO,
Non vascular death	0.72 [0.49 1.05]	p=1.00	0	18624	1	PLATO,
stroke (fatal and non fatal)	1.18 [0.91 1.53]	p=1.00	0	19285	2	PLATO, DISPERSE-2 (90mg),
myocardial infarction (fatal and non fatal)	0.84 [0.75 0.95]	p=0.04	0	19285	2	PLATO, DISPERSE-2 (90mg),
cardiovascular events	0.85 [0.78 0.94]	p=0.04	0	19285	2	PLATO, DISPERSE-2 (90mg),
Stent thrombosis (any, end of follow up)	no data
non cardiovascular death	no data
death, MI, unplanned revascularization	no data
ischemic events + bleeding	no data
major bleeding TIMI	no data
TIMI minor bleeding	no data
refractory ischemia	no data
fatal bleeding	0.87 [0.48 1.58]	p=1.00	0	18624	1	PLATO,
Major or minor TIMI bleeding	no data
Urgent target-vessel revascularization	no data
all cause death, MI, stroke	0.84 [0.77 0.92]	p=0.04	0	18624	1	PLATO,
net benefit	no data
stent thrombosis	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
PLATO, 2009	ticagrelor 90mg twice daily	clopidogrel 75mg once daily	patients with an acute coronary syndrome, with or without ST-segment elevation (onset of symptoms within the previous 24h).
DISPERSE-2 (90mg), 2007	ticagrelor 90 mg twice daily	clopidogrel	patients with NSTE-ACS, treated with aspirin and standard therapy for ACS

Cangrelor

acute coronary syndrome, in all type of patients

vs clopidogrel up front

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	1.59 [0.52 4.87]	p=1.00	0	7754	1	CHAMPION-PCI,
Bleeding	no data
Cardiovascular death	no data
MACE	0.67 [0.40 1.14]	p=1.00	0	7754	1	CHAMPION-PCI,
Revascularization	no data
Major bleeding	no data
Major bleeding	no data
Vascular death	no data
Non fatal stroke	no data
Non fatal MI	no data
ischemic stroke	no data
Non vascular death	no data
stroke (fatal and non fatal)	0.85 [0.29 2.54]	p=1.00	0	7754	1	CHAMPION-PCI,
myocardial infarction (fatal and non fatal)	0.40 [0.12 1.27]	p=1.00	0	7754	1	CHAMPION-PCI,
cardiovascular events	1.04 [0.88 1.24]	p=1.00	0	7754	1	CHAMPION-PCI,
Stent thrombosis (any, end of follow up)	no data
non cardiovascular death	no data
death, MI, unplanned revascularization	no data
ischemic events + bleeding	no data
major bleeding TIMI	no data
TIMI minor bleeding	no data
refractory ischemia	no data
fatal bleeding	no data
Major or minor TIMI bleeding	no data
Urgent target-vessel revascularization	no data
all cause death, MI, stroke	no data
net benefit	no data
stent thrombosis	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
CHAMPION-PCI, 2009	cangrelor up front (cangrelor administered before percutaneous coronary intervention and followed by clopidogrel)	clopidogrel up front (clopidogrel followed by placebo)	high risk patients requiring PCI

Cangrelor

acute coronary syndrome, in all type of patients

vs delayed clopidogrel

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
Bleeding	no data
Cardiovascular death	no data
MACE	no data
Revascularization	no data
Major bleeding	no data
Major bleeding	no data
Vascular death	no data
Non fatal stroke	no data
Non fatal MI	no data
ischemic stroke	no data
Non vascular death	no data
stroke (fatal and non fatal)	1.15 [0.39 3.44]	p=1.00	0	5355	1	CHAMPION-PLATFORM,
myocardial infarction (fatal and non fatal)	0.91 [0.74 1.13]	p=1.00	0	5355	1	CHAMPION-PLATFORM,
cardiovascular events	0.87 [0.71 1.07]	p=1.00	0	5355	1	CHAMPION-PLATFORM,
Stent thrombosis (any, end of follow up)	no data
non cardiovascular death	no data
death, MI, unplanned revascularization	no data
ischemic events + bleeding	no data
major bleeding TIMI	no data
TIMI minor bleeding	no data
refractory ischemia	no data
fatal bleeding	no data
Major or minor TIMI bleeding	no data
Urgent target-vessel revascularization	no data
all cause death, MI, stroke	no data
net benefit	no data
stent thrombosis	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
CHAMPION-PLATFORM, 2009	cangrelor up front (cangrelor during PCI followed by 600 mg of clopidogrel)	delayed clopidogrel (placebo during PCI followed by 600 mg of clopidogrel)	patients with acute coronary syndrome undergoing percutaneous coronary intervention

Prasugrel

acute coronary syndrome, in all type of patients

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.95 [0.78 1.17]	p=1.00	0	13608	1	TRITON-TIMI 38,
Bleeding	1.31 [1.10 1.56]	p=0.04	0	13608	1	TRITON-TIMI 38,
Cardiovascular death	no data
MACE	no data
Revascularization	0.67 [0.54 0.82]	p=0.04	0	13608	1	TRITON-TIMI 38,
Major bleeding	1.31 [1.02 1.68]	p=0.04	0	13608	1	TRITON-TIMI 38,
Major bleeding	1.31 [1.02 1.68]	p=0.04	0	13608	1	TRITON-TIMI 38,
Vascular death	0.88 [0.70 1.12]	p=1.00	0	13608	1	TRITON-TIMI 38,
Non fatal stroke	1.01 [0.71 1.45]	p=1.00	0	13608	1	TRITON-TIMI 38,
Non fatal MI	0.76 [0.67 0.87]	p=0.04	0	13608	1	TRITON-TIMI 38,
ischemic stroke	no data
Non vascular death	no data
stroke (fatal and non fatal)	no data
myocardial infarction (fatal and non fatal)	no data
cardiovascular events	no data
Stent thrombosis (any, end of follow up)	no data
non cardiovascular death	no data
death, MI, unplanned revascularization	no data
ischemic events + bleeding	no data
major bleeding TIMI	no data
TIMI minor bleeding	no data
refractory ischemia	no data
fatal bleeding	4.19 [1.58 11.12]	p=0.04	0	13608	1	TRITON-TIMI 38,
Major or minor TIMI bleeding	no data
Urgent target-vessel revascularization	no data
all cause death, MI, stroke	no data
net benefit	no data
stent thrombosis	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
JUMBO-TIMI 26, 2005	Prasugrel 3 doses	clopidogrel 300mg loading dose followed by 75 mg daily)	patients undergoing elective or urgent percutaneous coronary intervention
TRITON-TIMI 38, 2007	prasugrel 60-mg loading dose and 10-mg daily maintenance dose, for 6 to 15 months	clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose) for 6 to 15 months	patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled percutaneous coronary intervention

New P2Y12 Inhibitors